Moderna’s COVID-19 Vaccine FDA Briefing Mentions Cystic Fibrosis

Since the beginning of the COVID-19 vaccine development process, Moderna has sought to be incredibly transparent with the trial population – from age groupings, to racial identifiers and risk groups. Today’s release of data about their vaccine candidate has not been any different. Embedded in the FDA’s briefing document on the Moderna COVID-19 Vaccine, the...
Continue reading...